Symbols / GRTX
GRTX Chart
About
Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development of a portfolio of small molecule dismutase (SOD) mimetics to improve radiotherapy in cancer. The company's lead product is tilarginine that is in Phase 1/2 trial of a pan-inhibitor of nitric oxide synthase to treat patients with highly resistant forms of breast cancer, including metaplastic breast cancer (MpBC) and other refractory subsets of triple-negative breast cancer (TNBC). It develops avasopasem manganese, a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy that is in Phase 2a clinical trial. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 2.49M |
| Enterprise Value | 151.64M | Income | -8.99M | Sales | — |
| Book/sh | -1.98 | Cash/sh | 0.06 | Dividend Yield | — |
| Payout | 0.00% | Employees | 3 | IPO | — |
| P/E | — | Forward P/E | -0.03 | PEG | — |
| P/S | — | P/B | -0.02 | P/C | — |
| EV/EBITDA | -24.69 | EV/Sales | — | Quick Ratio | 7.48 |
| Current Ratio | 8.20 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -0.10 | EPS next Y | -1.24 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2023-11-14 07:00 | ROA | -55.36% |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 75.46M |
| Shs Float | 44.19M | Short Float | 5.28% | Short Ratio | 1.16 |
| Short Interest | — | 52W High | 0.04 | 52W Low | 0.01 |
| Beta | 1.96 | Avg Volume | 39.26K | Volume | 61.10K |
| Target Price | — | Recom | None | Prev Close | $0.03 |
| Price | $0.03 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.03
Latest analyst target
3. DCF / Fair value
$-0.82
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.03
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2023-08-29 | main | Citigroup | Neutral → Neutral | $0 |
| 2023-08-16 | down | HC Wainwright & Co. | Buy → Neutral | $0 |
| 2023-08-10 | down | Piper Sandler | Overweight → Neutral | $1 |
| 2023-07-17 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2023-03-22 | main | HC Wainwright & Co. | — → Buy | $6 |
| 2023-02-21 | init | Piper Sandler | — → Overweight | $6 |
| 2023-02-16 | up | B of A Securities | Underperform → Buy | $7 |
| 2023-02-16 | reit | HC Wainwright & Co. | — → Buy | $10 |
| 2022-05-27 | down | B of A Securities | Neutral → Underperform | $2 |
| 2021-12-20 | main | Citigroup | — → Buy | $20 |
| 2021-12-15 | up | HC Wainwright & Co. | Neutral → Buy | $10 |
| 2021-12-15 | up | BTIG | Neutral → Buy | $15 |
| 2021-10-20 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2021-10-19 | down | BTIG | Buy → Neutral | — |
| 2020-12-16 | up | Credit Suisse | Neutral → Outperform | $15 |
| 2020-12-07 | init | HC Wainwright & Co. | — → Buy | $15 |
| 2020-11-11 | main | Credit Suisse | — → Neutral | $9 |
| 2020-07-29 | main | Credit Suisse | — → Neutral | $8 |
| 2019-12-02 | init | BTIG | — → Buy | $30 |
| 2019-12-02 | init | B of A Securities | — → Buy | $15 |
- Galera Therapeutics Updates Preferred Stock Conversion Provisions - TipRanks Wed, 18 Feb 2026 11
- Galera Therapeutics Inc. (GRTX) reports earnings - qz.com Mon, 31 Mar 2025 07
- Galera Therapeutics Grants Retention Bonus to Key Officer - TipRanks hu, 12 Feb 2026 08
- Why Is Galera Therapeutics (GRTX) Stock Down 83% Today? - InvestorPlace hu, 10 Aug 2023 07
- Galera Therapeutics Completes Nova Pharmaceuticals Acquisition - citybiz ue, 31 Dec 2024 08
- Galera Therapeutics completes acquisition of Nova Pharmaceuticals - Nasdaq ue, 31 Dec 2024 08
- Galera Therapeutics sidesteps liquidation, acquires New York biotech company - The Business Journals ue, 31 Dec 2024 08
- Galera Therapeutics settles lawsuit for $975,000 - Investing.com hu, 08 Aug 2024 07
- Here’s Why Galera Therapeutics (GRTX) Stock Price Soared 180.4% Today - AskTraders.com ue, 14 Dec 2021 08
- Piper Sandler Initiates Coverage of Galera Therapeutics With Overweight Recommendation - 24/7 Wall St. ue, 21 Feb 2023 08
- Why Is Amyris (AMRS) Stock Down 67% Today? - InvestorPlace hu, 10 Aug 2023 07
- Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday - InvestorPlace Mon, 22 Apr 2024 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 70000 | 1407 | — | Sale at price 0.02 per share. | SORENSEN MELINDA | Chief Executive Officer | — | 2025-11-20 00:00:00 | D |
| 1 | 7644932 | 206413 | — | Purchase at price 0.03 per share. | CHANG NANCY T | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2024-12-30 00:00:00 | D |
| 2 | 67015 | 4825 | — | Sale at price 0.07 per share. | SORENSEN J. MEL | Chief Executive Officer | — | 2024-08-16 00:00:00 | D |
| 3 | 2780407 | 571538 | — | Purchase at price 0.18 - 0.23 per share. | SCHNEID YAIR | Beneficial Owner of more than 10% of a Class of Security | — | 2024-04-19 00:00:00 | D |
| 4 | 4200000 | 811848 | — | Sale at price 0.15 - 0.23 per share. | ALTAMONT PHARMACEUTICAL HOLDINGS LLC | Beneficial Owner of more than 10% of a Class of Security | — | 2024-03-28 00:00:00 | I |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -61.17K | 0.00 | -1.00 | 0.00 |
| TaxRateForCalcs | 0.01 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -13.58M | -45.10M | -50.61M | -72.56M |
| TotalUnusualItems | -5.56M | -2.31M | -1.00K | -4.00K |
| TotalUnusualItemsExcludingGoodwill | -5.56M | -2.31M | -1.00K | -4.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -18.96M | -59.08M | -62.22M | -80.53M |
| ReconciledDepreciation | 20.00K | 259.00K | 114.00K | 778.00K |
| EBITDA | -19.14M | -47.41M | -50.61M | -72.56M |
| EBIT | -19.16M | -47.67M | -50.72M | -73.34M |
| NetInterestIncome | 554.00K | -9.82M | -11.06M | -7.16M |
| InterestExpense | 0.00 | 11.41M | 11.57M | 7.19M |
| InterestIncome | 554.00K | 1.59M | 506.00K | 32.00K |
| NormalizedIncome | -13.46M | -56.77M | -62.22M | -80.53M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -18.96M | -59.08M | -62.22M | -80.53M |
| TotalExpenses | 14.15M | 46.95M | 51.23M | 73.37M |
| TotalOperatingIncomeAsReported | -20.16M | -49.26M | -51.23M | -73.37M |
| DilutedAverageShares | 54.63M | 44.55M | 27.09M | 25.79M |
| BasicAverageShares | 54.63M | 44.55M | 27.09M | 25.79M |
| DilutedEPS | -0.34 | -1.33 | -2.30 | -3.12 |
| BasicEPS | -0.34 | -1.33 | -2.30 | -3.12 |
| DilutedNIAvailtoComStockholders | -18.96M | -59.08M | -62.22M | -80.53M |
| NetIncomeCommonStockholders | -18.96M | -59.08M | -62.22M | -80.53M |
| NetIncome | -18.96M | -59.08M | -62.22M | -80.53M |
| NetIncomeIncludingNoncontrollingInterests | -18.96M | -59.08M | -62.22M | -80.53M |
| NetIncomeContinuousOperations | -18.96M | -59.08M | -62.22M | -80.53M |
| TaxProvision | -203.00K | 0.00 | -70.00K | 0.00 |
| PretaxIncome | -19.16M | -59.08M | -62.29M | -80.53M |
| OtherIncomeExpense | -5.56M | -2.31M | -1.00K | -4.00K |
| SpecialIncomeCharges | -6.01M | -2.31M | 0.00 | |
| OtherSpecialCharges | 2.87M | |||
| ImpairmentOfCapitalAssets | 3.14M | 0.00 | ||
| RestructuringAndMergernAcquisition | 0.00 | 2.31M | 0.00 | |
| GainOnSaleOfSecurity | 446.00K | -3.00K | -1.00K | -4.00K |
| NetNonOperatingInterestIncomeExpense | 554.00K | -9.82M | -11.06M | -7.16M |
| InterestExpenseNonOperating | 0.00 | 11.41M | 11.57M | 7.19M |
| InterestIncomeNonOperating | 554.00K | 1.59M | 506.00K | 32.00K |
| OperatingIncome | -14.15M | -46.95M | -51.23M | -73.37M |
| OperatingExpense | 14.15M | 46.95M | 51.23M | 73.37M |
| ResearchAndDevelopment | 3.15M | 24.11M | 31.01M | 52.42M |
| SellingGeneralAndAdministration | 11.00M | 22.84M | 20.21M | 20.95M |
| GeneralAndAdministrativeExpense | 11.00M | 22.84M | 20.21M | 20.95M |
| OtherGandA | 11.00M | 22.84M | 20.21M | 20.95M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 75.46M | 54.39M | 28.51M | 26.46M |
| ShareIssued | 75.46M | 54.39M | 28.51M | 26.46M |
| TotalDebt | 0.00 | 1.25M | 44.00K | 302.00K |
| TangibleBookValue | -148.04M | -134.32M | -112.32M | -61.14M |
| InvestedCapital | -148.04M | -131.19M | -109.18M | -58.00M |
| WorkingCapital | 8.34M | 16.67M | 25.16M | 64.46M |
| NetTangibleAssets | -143.67M | -134.32M | -112.32M | -61.14M |
| CapitalLeaseObligations | 0.00 | 1.25M | 44.00K | 302.00K |
| CommonStockEquity | -148.04M | -131.19M | -109.18M | -58.00M |
| PreferredStockEquity | 4.37M | |||
| TotalCapitalization | -143.67M | -131.19M | -109.18M | -58.00M |
| TotalEquityGrossMinorityInterest | -143.67M | -131.19M | -109.18M | -58.00M |
| StockholdersEquity | -143.67M | -131.19M | -109.18M | -58.00M |
| GainsLossesNotAffectingRetainedEarnings | 0.00 | -22.00K | -14.00K | |
| OtherEquityAdjustments | -22.00K | -14.00K | ||
| RetainedEarnings | -456.36M | -437.41M | -378.32M | -316.10M |
| AdditionalPaidInCapital | 308.25M | 306.17M | 269.14M | 258.09M |
| CapitalStock | 4.45M | 54.00K | 28.00K | 26.00K |
| CommonStock | 75.00K | 54.00K | 28.00K | 26.00K |
| PreferredStock | 4.37M | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 153.77M | 157.33M | 153.22M | 141.31M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 152.10M | 152.37M | 139.84M | 128.38M |
| OtherNonCurrentLiabilities | 151.05M | 151.05M | 139.63M | 128.06M |
| DerivativeProductLiabilities | 1.05M | 0.00 | ||
| NonCurrentDeferredLiabilities | 0.00 | 203.00K | 203.00K | 273.00K |
| NonCurrentDeferredTaxesLiabilities | 0.00 | 203.00K | 203.00K | 273.00K |
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 1.12M | 0.00 | 44.00K |
| LongTermCapitalLeaseObligation | 0.00 | 1.12M | 0.00 | 44.00K |
| CurrentLiabilities | 1.67M | 4.96M | 13.38M | 12.94M |
| CurrentDebtAndCapitalLeaseObligation | 133.00K | 44.00K | 258.00K | |
| CurrentCapitalLeaseObligation | 0.00 | 133.00K | 44.00K | 258.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 48.00K | 121.00K | 2.65M | 2.04M |
| PayablesAndAccruedExpenses | 1.62M | 4.70M | 10.68M | 10.64M |
| CurrentAccruedExpenses | 343.00K | 3.33M | 7.10M | 5.59M |
| Payables | 1.27M | 1.38M | 3.58M | 5.04M |
| AccountsPayable | 1.27M | 1.38M | 3.58M | 5.04M |
| TotalAssets | 10.10M | 26.14M | 44.04M | 83.31M |
| TotalNonCurrentAssets | 100.00K | 4.51M | 5.50M | 5.92M |
| OtherNonCurrentAssets | 100.00K | 90.00K | 1.88M | 1.96M |
| GoodwillAndOtherIntangibleAssets | 0.00 | 3.14M | 3.14M | 3.14M |
| OtherIntangibleAssets | 2.26M | 2.26M | 2.26M | |
| Goodwill | 0.00 | 881.00K | 881.00K | 881.00K |
| NetPPE | 0.00 | 1.28M | 481.00K | 823.00K |
| AccumulatedDepreciation | 0.00 | -459.00K | -1.70M | -1.59M |
| GrossPPE | 0.00 | 1.74M | 2.18M | 2.41M |
| Leases | 0.00 | 46.00K | 270.00K | 264.00K |
| OtherProperties | 1.40M | 1.38M | ||
| MachineryFurnitureEquipment | 0.00 | 484.00K | 471.00K | 471.00K |
| BuildingsAndImprovements | 0.00 | 1.21M | 43.00K | 296.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 10.00M | 21.63M | 38.53M | 77.39M |
| OtherCurrentAssets | 282.00K | 620.00K | 6.89M | 6.17M |
| RestrictedCash | 0.00 | 50.00K | 0.00 | |
| PrepaidAssets | 795.00K | 2.75M | 6.17M | |
| Receivables | 635.00K | 0.00 | ||
| OtherReceivables | 635.00K | |||
| CashCashEquivalentsAndShortTermInvestments | 8.29M | 18.26M | 31.60M | 71.22M |
| OtherShortTermInvestments | 0.00 | 27.33M | 51.36M | |
| CashAndCashEquivalents | 8.29M | 18.26M | 4.27M | 19.86M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -12.14M | -44.91M | -43.45M | -68.24M |
| IssuanceOfCapitalStock | 2.22M | 29.30M | 3.81M | 7.94M |
| CapitalExpenditure | -59.00K | -25.00K | -283.00K | |
| EndCashPosition | 8.29M | 18.26M | 4.32M | 19.86M |
| BeginningCashPosition | 18.26M | 4.32M | 19.86M | 15.87M |
| ChangesInCash | -9.97M | 13.94M | -15.54M | 3.99M |
| FinancingCashFlow | 2.22M | 31.50M | 3.89M | 66.71M |
| CashFlowFromContinuingFinancingActivities | 2.22M | 31.50M | 3.89M | 66.71M |
| NetOtherFinancingCharges | 57.50M | |||
| ProceedsFromStockOptionExercised | 0.00 | 2.20M | 81.00K | 1.27M |
| NetCommonStockIssuance | 2.22M | 29.30M | 3.81M | 7.94M |
| CommonStockIssuance | 2.22M | 29.30M | 3.81M | 7.94M |
| InvestingCashFlow | -46.00K | 27.29M | 23.99M | 5.24M |
| CashFlowFromContinuingInvestingActivities | -46.00K | 27.29M | 23.99M | 5.24M |
| NetInvestmentPurchaseAndSale | 0.00 | 27.35M | 24.02M | 5.52M |
| SaleOfInvestment | 0.00 | 49.99M | 83.91M | 77.50M |
| PurchaseOfInvestment | 0.00 | -22.64M | -59.89M | -71.98M |
| NetBusinessPurchaseAndSale | -50.00K | 0.00 | ||
| PurchaseOfBusiness | -50.00K | 0.00 | ||
| NetPPEPurchaseAndSale | 4.00K | -59.00K | -25.00K | -283.00K |
| SaleOfPPE | 4.00K | 0.00 | ||
| PurchaseOfPPE | 0.00 | -59.00K | -25.00K | -283.00K |
| OperatingCashFlow | -12.14M | -44.85M | -43.43M | -67.96M |
| CashFlowFromContinuingOperatingActivities | -12.14M | -44.85M | -43.43M | -67.96M |
| ChangeInWorkingCapital | -2.13M | -2.93M | 17.00K | -2.63M |
| ChangeInOtherWorkingCapital | -3.24M | |||
| ChangeInOtherCurrentLiabilities | -38.00K | -104.00K | -258.00K | -307.00K |
| ChangeInOtherCurrentAssets | 89.00K | 1.93M | 330.00K | -246.00K |
| ChangeInPayablesAndAccruedExpense | -4.47M | -8.51M | 658.00K | -1.05M |
| ChangeInAccruedExpense | -3.06M | -6.30M | 2.12M | -951.00K |
| ChangeInPayable | -1.42M | -2.21M | -1.46M | -101.00K |
| ChangeInAccountPayable | -1.42M | -2.21M | -1.46M | -101.00K |
| ChangeInPrepaidAssets | 2.29M | 514.00K | 2.53M | -1.02M |
| ChangeInReceivables | 0.00 | 3.24M | -3.24M | |
| OtherNonCashItems | 3.84M | 11.41M | 11.57M | 7.19M |
| StockBasedCompensation | 2.54M | 5.56M | 7.16M | 7.23M |
| AssetImpairmentCharge | 3.14M | 0.00 | ||
| DeferredTax | -203.00K | 0.00 | -70.00K | 0.00 |
| DeferredIncomeTax | -203.00K | 0.00 | -70.00K | 0.00 |
| DepreciationAmortizationDepletion | 20.00K | 259.00K | 114.00K | 778.00K |
| DepreciationAndAmortization | 20.00K | 259.00K | 114.00K | 778.00K |
| OperatingGainsLosses | -404.00K | -72.00K | ||
| GainLossOnInvestmentSecurities | -452.00K | |||
| GainLossOnSaleOfPPE | 48.00K | -72.00K | 0.00 | |
| NetIncomeFromContinuingOperations | -18.96M | -59.08M | -62.22M | -80.53M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for GRTX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|